RhumbLine Advisers’s Telix Pharmaceuticals TLX Stock Holding History

RhumbLine Advisers’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$78.6K	Sell	7,168 -750	-9%	-$8.51K	﹤0.01%	3561
2026 Q2	$91.3K	Sell	7,918 -1,905	-19%	-$19.4K	﹤0.01%	3558
2026 Q1	$94K	Sell	9,823 -964	-9%	-$7.34K	﹤0.01%	3438
2025 Q4	$80.8K	Buy	10,787 +8,208	+318%	+$79K	﹤0.01%	3540
2025 Q3	$24.7K	Buy	2,579 +1,392	+117%	+$17.1K	﹤0.01%	3753
2025 Q2	$19.2K	Buy	1,187 +41	+4%	+$688	﹤0.01%	3800
2025 Q1	$19.2K	Buy	+1,146	New	+$20K	﹤0.01%	3749

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return

Portland Investment Counsel Burlington, Ontario, Canada $339M AUM 1.43% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Brinker Capital Investments Berwyn, Pennsylvania $17.5B AUM 20.48% 1-Year Est. Return

RhumbLine Advisers's TLX Position: Q3 2026 in Review

RhumbLine Advisers reduced its Telix Pharmaceuticals (TLX) stake by 9.5% in Q3 2026, selling an estimated $8.51K and leaving 7,168 shares worth $78.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

RhumbLine Advisers first reported a position in TLX in Q1 2025 and has held it in 7 quarters since. The position peaked at $94K in Q1 2026. 50 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

RhumbLine Advisers held 7,168 shares of Telix Pharmaceuticals worth $78.6K as of Q3 2026.
RhumbLine Advisers sold 750 Telix Pharmaceuticals shares in Q3 2026, an estimated $8.51K.
Telix Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3561 holding.
RhumbLine Advisers first reported a position in Telix Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
RhumbLine Advisers's Telix Pharmaceuticals position peaked at $94K in Q1 2026.
50 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.